A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone

NCT02675426 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

661

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: Placebo
DRUG: Upadacitinib

Sponsor

AbbVie